Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$18.33 -6.1%	$18.99	$14.40 ▼ $47.00	$1.30B	1.39	889,846 shs	1.00 million shs
DVAX Dynavax Technologies	$9.41 -2.9%	$12.24	$9.28 ▼ $14.63	$1.15B	1.26	2.22 million shs	2.03 million shs
INVA Innoviva	$18.56 -0.1%	$17.90	$15.20 ▼ $21.28	$1.16B	0.35	635,047 shs	445,747 shs
KERX Keryx Biopharmaceuticals	$3.36	$0.00	$2.47 ▼ $5.98	$344.00M	2.35	1.69 million shs	2.60 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-6.10%	-11.28%	+11.70%	-18.42%	-55.52%
DVAX Dynavax Technologies	-2.64%	-16.95%	-21.78%	-28.44%	-19.23%
INVA Innoviva	-0.11%	-0.85%	+7.16%	+0.76%	+19.28%
KERX Keryx Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.5119 of 5 stars	4.5	0.0	0.0	0.0	1.9	0.0	0.0
DVAX Dynavax Technologies	4.2739 of 5 stars	3.3	2.0	0.0	4.7	2.4	1.7	1.9
INVA Innoviva	4.1929 of 5 stars	3.5	0.0	0.0	4.2	2.8	2.5	1.9
KERX Keryx Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	194.05% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	155.05% Upside
INVA Innoviva	3.00	Buy	$55.00	196.34% Upside
KERX Keryx Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KERX, CLDX, DVAX, and INVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00
3/20/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$46.00
3/7/2025	INVA Innoviva	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$55.00
3/3/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$42.00 ➝ $36.00
2/28/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	173.34	N/A	N/A	$9.08 per share	2.02
DVAX Dynavax Technologies	$277.25M	4.15	N/A	N/A	$4.81 per share	1.96
INVA Innoviva	$369.84M	3.15	$3.59 per share	5.17	$10.66 per share	1.74
KERX Keryx Biopharmaceuticals	$60.64M	5.67	N/A	N/A	($0.12) per share	-28.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	N/A
DVAX Dynavax Technologies	-$6.39M	$0.18	52.28	19.20	N/A	9.85%	4.22%	2.67%	N/A
INVA Innoviva	$179.72M	-$1.01	26.90	11.97	N/A	18.31%	20.84%	11.38%	5/14/2025 (Estimated)
KERX Keryx Biopharmaceuticals	-$163.44M	-$0.88	N/A	N/A	N/A	-96.41%	N/A	-60.05%	N/A

Latest KERX, CLDX, DVAX, and INVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million
2/27/2025	Q4 2024	CLDX Celldex Therapeutics	-$0.73	-$0.71	+$0.02	-$0.71	$1.25 million	$1.18 million
2/26/2025	Q4 2024	INVA Innoviva	N/A	$0.57	N/A	$0.26	N/A	$91.81 million
2/20/2025	Q4 2024	DVAX Dynavax Technologies	$0.05	$0.05	N/A	$0.05	$72.70 million	$72.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
KERX Keryx Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
DVAX Dynavax Technologies	0.33	13.23	12.34
INVA Innoviva	0.38	1.79	1.64
KERX Keryx Biopharmaceuticals	N/A	2.21	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
INVA Innoviva	99.12%
KERX Keryx Biopharmaceuticals	69.00%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
DVAX Dynavax Technologies	2.98%
INVA Innoviva	2.25%
KERX Keryx Biopharmaceuticals	1.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
DVAX Dynavax Technologies	350	122.41 million	127.54 million	Optionable
INVA Innoviva	100	62.68 million	61.54 million	Optionable
KERX Keryx Biopharmaceuticals	N/A	102.38 million	N/A	Optionable

KERX, CLDX, DVAX, and INVA Headlines

Recent News About These Companies

Arkansas vs. Ole Miss kickoff time announced

October 28, 2024 | 247sports.com

LBTI Lithium & Boron Technology, Inc.

September 24, 2024 | seekingalpha.com

2024 Biopharmaceutical Industry Landscape

August 17, 2024 | morningstar.com

Caliway Biopharmaceuticals Co Ltd 6919

April 13, 2024 | morningstar.com

XTL Biopharmaceuticals Ltd ADR XTLB

November 15, 2023 | morningstar.com

ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)

September 11, 2023 | investing.com

Insulin-based versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes: Which is Better?

September 9, 2023 | medscape.com

Q2 2023 Westrock Coffee Co Earnings Call

August 13, 2023 | finance.yahoo.com

Update for Primary Healthcare Providers: Recent Statin Trials and Revised National Cholesterol Education Program III Guidelines

August 12, 2023 | medscape.com

Keryx CEO vs. a Short-Seller: Zerenex Patent Debate

July 29, 2023 | thestreet.com

Quality by design for biopharmaceuticals

July 10, 2023 | nature.com

8-K: CUTERA INC

May 12, 2023 | marketwatch.com

Manoj Madhavan

May 6, 2023 | seekingalpha.com

Biopharmaceuticals Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand and Forecast

May 3, 2023 | finance.yahoo.com

Mechanisms of Disease: Understanding Resistance of HER2-Targeted Therapy in Human Breast Cancer

April 30, 2023 | medscape.com

Staidson (Beijing) Biopharmaceuticals Co. Ltd.

April 13, 2023 | wsj.com

Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners

March 28, 2023 | finance.yahoo.com

Biopharmaceuticals Market 2023 Analysis by Market Size, New Technology, Growth Rate, Geographical Regions, Drivers and Outlook to 2027

January 29, 2023 | marketwatch.com

NAVB Navidea Biopharmaceuticals, Inc.

January 25, 2023 | seekingalpha.com

Biopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

January 25, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KERX, CLDX, DVAX, and INVA Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$18.33 -1.19 (-6.10%)

As of 05/9/2025 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$9.41 -0.28 (-2.89%)

As of 05/9/2025 03:59 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva NASDAQ:INVA

$18.56 -0.02 (-0.11%)

As of 05/9/2025 04:00 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Keryx Biopharmaceuticals NASDAQ:KERX

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time